Investors Overview

Overview

Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.




Minimum 15 minutes delayed. Source: LSEG

News Releases

10 Jun '26
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation of shares to a director of the board of Alvotech in accordance with his remuneration package.